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I n t r o d u c t i o n
Levamisole (LVM), the laevo-rotary isomer of tetramisole 
[2,3,5,6-tetrahydro 6–phenyl imidazo (2,1-b) thiazole] is a broad-
spectrum anthelmintic drug active against most nematodes (1) 
and widely used in veterinary medicine. Levamisole induces spas-
tic paralysis in the target nematodes as a result of permanent 
muscle contraction. Oxyclozanide (OXZ) [2,3,5-trichloro-N-(3,5-
dichloro-2-hydroxyphenyl)-6-hydroxybenzamide] is a salicylani-
lide anthelmintic drug that mainly acts by uncoupling oxidative 
phosphorylation in flukes (2,3). It is used for the treatment and 
control of adult stages of liver flukes in large and small ruminant 
species (4,5). Combination of anthelmintics formulated has been 
used to  provide positive results against resistant nematodes (6–8) 
and broad- spectrum control of different types of internal parasites, 
e.g.,  nematodes and tapeworms or nematodes and liver flukes in 
ruminants.
The extra-label use of drugs is a common practice in goats. The 
high prevalence of anthelmintic-resistant nematodes in goats is prob-
ably due to the extensive extra-label use of drug at the sheep doses 
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A b s t r a c t
Since there is no registered anthelmintic drug available for use in goats, extra-label use of drugs is a common practice in most 
countries. The aim of the present study was to compare the pharmacokinetic disposition of levamisole (LVM)-oxyclozanide 
(OXZ) combination in sheep and goats following per os administration. Goats (n = 8) and sheep (n = 8) 12- to 16-months-old were 
used for this study. The animals received tablet formulation of LVM and OXZ combination orally at a dose of 7.5 mg/kg and 
15 mg/kg body weight, respectively. Blood samples were collected by jugular vein at different times between 5 min and 120 h 
after drug administrations. The plasma concentrations of LVM and OXZ were analyzed by HPLC following liquid-liquid phase 
extraction procedures. The plasma concentrations and systemic availabilities of both LVM and OXZ in goats were lower and the 
plasma persistence of LVM was shorter compared with those observed in sheep. Terminal half-lives (t1/2z) of both molecules 
are shorter in goats compared with those in sheep. Goats treated with LVM-OXZ combination at the recommended dose for 
sheep may result in a reduced efficacy, because of under-dosing, which may increase the risk of drug resistance in parasites. 
Increased or repeated dose could be a strategy to provide higher plasma concentration and thus to improve the efficacy against 
the target parasites in goats compared with sheep. However, some adverse reactions may occur since LVM has relatively very 
narrow therapeutic index due to its nicotine-like structure and effect.
R é s u m é
Étant donné qu’il n’y a aucun anthelminthique homologué disponible pour utilisation chez les chèvres, l’utilisation hors-homologation de 
médicaments est une pratique usuelle dans la plupart des pays. L’objectif de la présente étude était de comparer la disposition pharmacocinétique 
de la combinaison levamisole (LVM)-oxyclozanide (OXZ) chez les moutons et les chèvres suite à l’administration per os. Des chèvres (n = 8) 
et des moutons (n = 8) âgés de 12 à 16 mois furent utilisés pour cette étude. Les animaux ont reçu une combinaison de comprimés de LVM 
et d’OXZ à une dose de 7,5 mg/kg et 15 mg/kg de poids corporel, respectivement. Des échantillons sanguins furent prélevés par ponction 
de la veine jugulaire à différents temps entre 5 min et 120 h suite à l’administration des médicaments. Les concentrations plasmatiques de 
LVM et d’OXZ furent analysées par HPLC suite à des procédures d’extraction de phase liquide-liquide. Les concentrations plasmatiques et 
les disponibilités systémiques de LVM et OXZ chez les chèvres étaient plus basses et la persistance plasmatique de LVM de plus courte durée 
comparativement à celles observées chez les moutons. Les demi-vies terminales (t1/2z) des deux molécules sont plus courtes chez les chèvres 
comparativement à celles chez les moutons. Le traitement de chèvres avec la combinaison LVM-OXZ au dosage recommandé pour les moutons 
pourrait résulter en une efficacité moindre, dû à un sous-dosage, ce qui pourrait augmenter le risque de résistance au médicament chez les 
parasites. Des doses augmentées ou répétées pourraient s’avérer une stratégie pour obtenir des concentrations plasmatiques plus élevées et 
ainsi améliorer l’efficacité contre les parasites ciblés chez les chèvres comparativement aux moutons. Toutefois, quelques réactions indésirables 
peuvent survenir étant donné que le LVM a déjà un index thérapeutique assez étroit associé à sa structure et son effet apparentés à la nicotine.
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recommended, corresponding to a drug under-dosage. It has been 
reported that the metabolism of many therapeutic drugs, including 
anthelmintics, differs between sheep and goats (9–17). The drug 
molecules are more rapidly metabolized and eliminated from blood 
in goats compared with sheep. Hence, administration of anthelmintic 
drugs to goats at an ovine dosage has resulted in a reduced efficacy, 
because of under-dosing. This may explain the differences in the 
prevalence of anthelmintic resistance in nematode populations in 
goats compared with sheep in particular for multi-resistant strains 
(14,18). Therefore, the purposes of this study were to compare the 
pharmacokinetic disposition of LVM-OXZ combination in sheep and 
goats and to find out whether the dose recommended for sheep can 
be applied in goats following per os administration.
M a t e r i a l s  a n d  m e t h o d s
Experimental animals
Eight goats [mean body weight (BW): 23.1 6 4.2 kg] and 8 sheep 
(mean BW: 24.8 6 2.9 kg) that were 12- to 16-months old were used 
in this investigation. They were housed and fed with wheat straw, 
fodder, and concentrate feed. Water was supplied ad libitum. This 
study was approved by Animal Ethic Committee of University of 
Adnan Menderes.
Treatment and sampling
The animals received tablet formulation of LVM and OXZ combi-
nation (Zelensin, 375 mg LVM HCl 1 750 mg OXZ, Sanovel, Istanbul, 
Turkey) orally at a dose of 7.5 mg/kg BW and 15 mg/kg BW, respec-
tively. Heparinized blood samples (5 mL) were collected by jugular 
venipuncture prior to drug administration then at 5, 10, 15, and 
30 min, 1, 1.5, 2, 4, 8, 12, 16, 24, 32, 48 h and 3, 4, 5, 6, and 8 days.
Analytical procedures
The plasma concentrations of LVM and OXZ were analyzed by 
high-performance liquid chromatography (HPLC) following liquid-
liquid phase extraction. Stock solutions (100 mg/mL) of pure stan-
dard of LVM hydrochloride and OXZ (Sigma, St. Louis, Missouri, 
USA) were prepared using acetonitrile and water (50:50) as the 
solvent. These were diluted to give 0.01, 0.05, 0.1, 0.5, 1, 5, 10, and 
20 mg/mL standard solutions for plasma for calibration as standard 
curves and to add to drug-free plasma samples to determine the 
recovery of both molecules.
Extraction from plasma
Plasma concentrations of LVM and OXZ were determined by 
HPLC with ultraviolet detection according to methods previously 
described by Garcia et al (19) and Jo et al (20) with some modifica-
tions, respectively.
For LVM analysis, drug-free plasma samples (1 mL) were spiked 
with standard of LVM to reach the following final concentrations: 
0.025, 0.05, 0.1, 0.5, 1 and 5 mg/mL. Water (1 mL) and 0.5 mL of 
10 N sodium hydroxide were added to 10 mL-ground glass tubes 
containing 1 mL spiked or experimental plasma samples. After 
mixing by vortex for 15 seconds, 6 mL ethyl ether:nhexane (80:20, 
vol/vol), was added. The sample tubes were stoppered and shaken 
for 10 min on a rotary mixer. After centrifugation at 3000 3 g for 
10 min, the upper organic phase was transferred to a thin-walled 
10 mL-conical glass tube and evaporated to dryness at 40°C in a 
rota vapor (Maxi-Dry plus, Heto, Denmark). The dry residue was 
reconstituted with 250 mL mobile phase. Then, the tubes were placed 
in an ultrasonic bath and finally, 50 mL of this solution was injected 
into the chromatographic system.
For OXZ analysis, drug-free plasma samples (1 mL) were spiked 
with standard of OXZ to reach the following final concentrations: 
0.05, 0.1, 0.5, 5, 10, and 20 mg/mL. Acetonitrile (2 mL) was added, 
and the sample was mixed by vortex (10 s). Anhydrous sodium 
sulphate (1 g) was added, and the sample tubes were stoppered and 
shaken for 10 min on a rotary mixer. The samples were centrifuged 
at 3000 3 g for 10 min thereafter, and extracted once again with 2 mL 
of acetonitrile. The organic layers were recovered after 20 min of 
centrifugation at 3000 3 g. Then n-hexane (5 mL) was added to the 
combined supernatant. After shaking, the upper phase was discarded 
after 10 min of centrifugation at 3000 3 g. The lower phase was 
transferred to a thin-walled 10 mL-conical glass tube and evaporated 
to dryness at 40°C in a rota vapor (Maxi-Dry plus). The dry residue 
was reconstituted with 250 mL mobile phase. Then, the tubes were 
placed in an ultrasonic bath and finally, 50 mL of this solution was 
injected into the chromatographic system.
High-performance liquid chromatography system
The mobile phase consisted of acetonitrile and water (2% ace-
tic acid) (20:70, v/v) and was delivered (1100 Series, QuatPump 
Agilent, Waldron, Germany) at an isocratic flow rate of 1 mL/min. 
A nucleosil C18 analytical column (Luna, 4 mm, 150 mm 3 4.6 mm; 
Phenomenex, Macclesfield, Cheshire, UK) with nucleosil C18 guard 
column was used for analysis of the molecules. Ultraviolet detection 
(1100 Series, Agilent, Waldron, Germany) was at a wavelength of 
225 nm for LVM analysis.
Oxyclozanide were determined using same HPLC system and 
eluted with a mobile phase consisting of a mixture of acetonitrile 
and 0.1% phosphoric acid (40:60, v/v). The isocratic mode was run 
at a flow rate of 1 mL/min and an ultraviolet detector was operated 
at 300 nm.
Method validation
The analytical methods used for LVM and OXZ in plasma samples 
were validated before analysis of the experimental samples. The 
analytes were identified with the retention time of pure reference 
standards. Recoveries of the molecules under study were measured 
by comparison of the peak areas from spiked plasma samples with 
the areas resulting from direct injections of standard solutions. The 
inter- and intra-assay precisions of the extraction and chromatog-
raphy procedures were evaluated by processing replicate aliquots 
of previously drug-free goat and sheep plasma samples containing 
known amounts of the drugs on different days.
The calibration graphs for LVM and OXZ were prepared (linear 
range 0.025 to 10 mg/mL). The slopes of the lines between peak areas 
and drug concentrations were determined by least squares linear 
regression and correlation coefficient (r) and coefficient of variations 
(CV) calculated. Linearity was established to determine the drug 
concentration/detector response relationship. The detection limits 
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of the both LVM and OXZ were established with HPLC analysis of 
blank plasma fortified with the standard, measuring the baseline 
noise at the retention time of the peak. The mean baseline noise at 
the peak retention time plus 3 standard deviations was defined as 
the detection limit (LOD). The mean baseline noise plus 6 standard 
deviations was defined as the limit of quantification (LOQ).
Pharmacokinetic and statistical analysis of data
The plasma concentration versus time curves obtained after each 
treatment in individual animals, were fitted with the WinNonlin 
software program (Version 5.2; Pharsight Corporation, Mountain 
View, California, USA). Pharmacokinetic parameters for each ani-
mal were analyzed using non-compartmental model analysis with 
extravascular input for LVM and OXZ. The maximum plasma con-
centration (Cmax) and time to reach maximum concentration (tmax) 
were obtained from the plotted concentration-time curve of each 
drug in each animal. The trapezoidal rule was used to calculate the 
area under the plasma concentration time curve (AUC). The mean 
residence time (MRT) was calculated as:
MRTlast = AUMClast/AUClast
Terminal half-life (t1/2z) was calculated as:
t1/2z = 2ln(2)/z
Where: z represents the first-order rate constant associated with 
the terminal (log linear) portion of the curve.
The pharmacokinetic parameters obtained from each animal were 
reported as a median with interquartile ranges (Q1–Q3) and statis-
tically compared by the Mann-Whitney U-test between sheep and 
goats. The values were considered significantly different at P , 0.05.
Re s u l t s
The analytic procedures and HPLC analysis of LVM and OXZ 
were validated before analysis of experimental samples. Mean recov-
eries of LVM and OXZ from plasma were 86.31% and 74.12% with 
a relative SD , 10%, respectively. The limit of detections and limit 
of quantification for LVM and OXZ were 0.014 to 0.043 mg/mL and 
0.011 to 0.032, respectively. The inter-assay and intra-assay precisions 
of the extraction and chromatography procedures were evaluated by 
processing on different days 6 replicate aliquots of drug-free sheep 
or goat plasma samples that contained known amounts of LVM and 
OXZ. The precision determined at each concentration was , 15% of 
the coefficient of variation, and accuracy ranged from 92% to 106% 
for both molecules.
Median (with Q1–Q3 ranges) pharmacokinetic parameters of LVM 
and OXZ combination in goats and sheep are shown in Table I with 
the plasma concentration versus time curves (Figures 1 and 2, respec-
tively). This study indicated that the plasma dispositions of both 
LVM and OXZ in goats were significantly different to those observed 
in sheep following oral administration at same dose rates. Although 
no significant difference was found for maximum plasma concentra-
tion (Cmax: 1.63 mg/mL versus 1.07 mg/mL), significantly larger area 
under the concentration vs. time curve (AUC: 8.75 mg.h/mL versus 
2.09 mg.h/mL), longer terminal half-life (t1/2z: 7.91 h versus 3.81 h) 
and mean residence time (MRT: 7.11 h versus 2.69 h) were observed 
Table I. Median pharmacokinetic parameters with the interquartile (IQ) ranges (Q1–Q3) 
of levamisole (LVM) and oxyclozanide (OXZ) combination in sheep and goats following 
single per os administration (n = 8)
 LVM (7.5 mg/kg) OXZ (15 mg/kg)
Parameters Sheep Goat Sheep Goat
t1/2z (h) 7.91** 3.81 21.74* 18.71
 (6.17–8.72) (2.856–4.297) (19.07–26.09) (14.55–19.90)
tmax (h) 0.83 0.83 20.00 24.00
 (0.083–0.083) (0.083–0.250) (12.00–24.00) (16.00–24.00)
Cmax (mg/mL) 1.63 1.07 11.01* 6.68
 (0.81–2.10) (0.78–1.71) (9.48–16.72) (4.92–9.03)
tlast (h) 20.00* 8.00 192.0* 156.0
 (13.00–32.00) (8.00–12.00) (174.0–210.0) (120.0–186.0)
AUClast (mg.h/mL) 8.75** 2.09 488.70* 309.33
 (3.76–11.19) (1.42–2.88) (322.0–786.0) (216.0–380.3)
MRTlast (h) 7.11** 2.69 38.39 35.97
 (4.71–10.51) (2.06–3.55) (36.33–42.92) (34.46–40.32)
t1/2z — terminal half-life; tmax — time to reach peak plasma concentration; Cmax — peak plasma 
concentration; tlast — time to last detectable plasma concentration; AUClast — area under the 
(zero moment) curve from time 0 to the last detectable concentration; MRTlast — mean residence 
time.
*The kinetic parameters of LVM or OXZ in sheep are significantly different (*P , 0.05, 
**P , 0.01) from goats.
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in sheep as compared with those observed in goats for LVM, respec-
tively. In addition, Cmax (11.01 mg/mL versus 6.68 mg/mL), AUC 
(488.70 mg.h/mL versus 309.33 mg.h/mL) and t1/2z (21.74 h versus 
18.71 h) values of OXZ in sheep were significantly higher and longer 
compared with those values observed in goats, respectively.
D i s c u s s i o n
The plasma concentrations of both LVM and OXZ in sheep were 
considerably higher and the plasma persistence of LVM was longer 
compared with those observed in goats following oral administra-
tion. The origin of the lower plasma concentration of both molecules 
in goats is unclear. The most likely explanation is that goats have 
greater metabolic capacity and elimination capability of anthelmintic 
compounds than do sheep, as has been previously demonstrated 
with LVM (21) and other broad-spectrum anthelmintic groups such 
as benzimidazoles (10) and macrocyclic lactones (22–24). Moreover, it 
was reported that goats were better adapted to tolerate and detoxify 
plant toxins compared with sheep (25,26).
Levamisole rapidly reached the plasma peak concentrations at 
0.08 h in sheep and goats after oral administration. These values 
are similar to those obtained by Galtier et al (21) in sheep (0.083 h) 
and goats (0.166 h). On the other hand, Cmax (1.63 mg/mL and 
1.07 mg/mL) and t1/2 (7.94 h and 3.67 h) values of LVM observed 
in the present study are higher and longer than those reported by 
Galtier et al (21) in sheep (Cmax: 1.06 mg/mL and t1/2: 1.2 h) and 
goats (Cmax: 0.63 mg/mL and t1/2: 1.25 h), respectively. In addition, 
Fernandez et al (27) and Sahagún et al (28) obtained much lower 
plasma concentration for LVM in sheep compared with the present 
study following per os administration at same rates. The origin of 
the differences between studies is unclear. These differences may in 
part be due to differences in methodology or experimental condi-
tions since different feeding regime, formulation, and parasitologi-
cal status could have caused differences in absorption, disposition, 
and persistence of anthelmintic drugs in the animals. In this study, 
tablet formulation of LVM/OXZ combination was administered to 
animals, whereas Galtier et al (21), and Fernandez et al (27), and 
Sahagún et al (28) administered LVM as an oral drench and solu-
tion, respectively. Moreover, there was the possibility of a drug-drug 
interaction, due to co-administration of both drugs. However, there 
is no information available in the literature on this kind of interac-
tion for LVM and OXZ.
The present study indicates that the plasma concentration of 
OXZ in sheep is significantly greater than that in goats. The Cmax 
(13.24 mg/mL) and AUC (621.46 mg.h/mL) values of OXZ in sheep 
more than 2 times higher and larger than those observed in goats 
(6.83 mg/mL and 294.70 mg.h/mL) after per os administration, 
respectively. Moreover, terminal half-life of OXZ in goats is signifi-
cantly shorter than that observed in sheep. Similar differences of 
OXZ as observed with LVM disposition between 2 species supports 
that goats have lower systemic availability and faster elimination 
process compared with sheep. As closantel and rafoxanide are the 
most widely used salicylanilide group anthelmintics, they are more 
extensively studied in different animal species [reviewed by Swan 
(29)]. Nevertheless, there is a paucity of data available in the litera-
tures on the pharmacokinetics of OXZ in animals and this is reported 
first herein. A radiolabel study of 14C-oxyclozanide was conducted 
in sheep following a single dose rate of 15 mg/kg BW formulated 
as a commercial drench (30). The highest plasma radioactivity of 
10 to 20 mg/mL (Cmax) was found at 8 h (tmax) after administration. 
Moreover, the plasma dispositions of rafoxanide, closantel, and OXZ 
in sheep following per os administration described by Mohammed-
Ali and Bogan (31). The findings of OXZ from the present study in 
sheep are not similar to those obtain by Mohammed-Ali and Bogan 
(31). Cmax (19.0 mg/mL), AUC (1224 mg.h/mL), and t1/2 (153.6 h) 
values of OXZ were much greater and longer compared with those 
observed in this study, respectively. These differences are probably 
related to the methodology of the previous study, since the number 
of sampling times seems insufficient to determine the actual param-
eters such as Cmax and t1/2 values.
In conclusion, the plasma concentrations of both LVM and OXZ 
in goats were significantly lower and the plasma persistence of LVM 
was significantly shorter compared with those observed in sheep 
following per os co-administration. Goats treated with LVM-OXZ 
Figure 1. Plasma disposition versus time curves of levamisole (LVM) in 
goats and sheep following single per os administration (n = 8).
Figure 2. Plasma disposition versus time curves of oxyclozanide (OXZ) in 
goats and sheep following single per os administration (n = 8).
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combination at the recommended dose for sheep may result in a 
reduced efficacy, because of under-dosing, which may increase the 
risk of drug resistance in internal parasites. Increased or repeated 
dose could be a strategy to provide higher and more persistent 
plasma concentration and thus improve the efficacy against the tar-
get parasites in goats compared with sheep. However, some adverse 
reactions may occur since LVM has a relatively narrow therapeutic 
index due to its nicotine-like structure and effect.
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